Has Devi Sampat, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,007 in general payments to Devi Sampat, MD across 597 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Devi Sampat, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Devi Sampat, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Devi Sampat, MD

Medical Oncology · Gainesville, GANPI 1104212778

Payments from drug & device makers

$13,007in general payments, 2019–2025

Across 597 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$846
Novartis$794
AstraZeneca$762
Merck$664
Daiichi Sankyo Inc.$592
Johnson & Johnson$589
plus $9K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	50	$846
Novartis	37	$794
AstraZeneca(2 entities)	35	$762
Merck	29	$664
Daiichi Sankyo Inc.	30	$592
Johnson & Johnson(2 entities)	22	$589
Incyte Corporation	21	$568
Eisai Inc.	21	$546
GSK	21	$501
Seagen Inc.	17	$463
Bristol Myers Squibb	21	$460
AbbVie	20	$453
Bayer	17	$392
Sanofi	17	$384
Genentech USA, Inc.	16	$335
E.r. Squibb & Sons, L.L.C.	16	$298
Takeda Pharmaceuticals U.S.A., Inc.	9	$260
Gilead(2 entities)	12	$249
Exelixis Inc.	11	$241
Amgen	10	$208
Jazz Pharmaceuticals Inc.	9	$201
Pharmacyclics LLC, An Abbvie Company	8	$193
Stemline Therapeutics Inc.	6	$192
Puma Biotechnology, Inc.	9	$188
Tersera Therapeutics LLC	7	$168
Regeneron Healthcare Solutions, Inc.	8	$163
Lilly USA, LLC	9	$162
Beigene USA, Inc.	7	$161
Coherus Oncology, Inc.	8	$143
EMD Serono, Inc.	7	$132
Astellas Pharma US Inc	5	$122
Deciphera Pharmaceuticals Inc.	6	$119
Rigel Pharmaceuticals, Inc.	6	$108
Beone Medicines USA, Inc.	5	$107
Servier Pharmaceuticals LLC	5	$98
Taiho Oncology, Inc.	3	$89
Karyopharm Therapeutics Inc.	4	$86
Morphosys, US Inc.	4	$79
Array Biopharma Inc	9	$74
Epizyme, Inc.	4	$69
Sobi, Inc	3	$63
Sumitomo Pharma America, Inc.	2	$48
Foundation Medicine, Inc.	2	$48
AVEO Pharmaceuticals, Inc.	2	$47
Tempus AI, Inc	2	$44
Organon	2	$42
Dova Pharmaceuticals	2	$40
Myovant Sciences Inc.	2	$39
Sun Pharmaceutical Industries Inc.	1	$35
Tolmar, Inc.	2	$32
Acrotech Biopharma Inc.	2	$32
Boehringer Ingelheim	1	$26
Pharmaessentia USA Corporation	1	$25
Immunogen, Inc.	1	$24
Fennec Pharmaceuticals, Inc.	1	$23
Mirati Therapeutics, Inc.	1	$23
Syndax Pharmaceuticals, Inc.	1	$20
Kyowa Kirin, Inc.	1	$20
Amneal Pharmaceuticals LLC	1	$20
CTI Biopharma Corp.	1	$18

How this compares

$13,007 in reported general payments places this provider in the 40th percentile of 68 medical oncology providers in Georgia.

See all medical oncology providers in Georgia →

Medicare billing

Part B allowed, 2024

$3,021,758

Medicare patients

552

Services billed

132,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Gainesville

Charles NashGainesville$258K
Andrew JohnsonGainesville$252K
Richard LociceroGainesville$33K
Venumadhav KotlaGainesville$24K
Yamin SunGainesville$17K
Shravanti MacherlaGainesville$14K
Timothy CareyGainesville$14K
Jennifer AndersonGainesville$12K
Nancy SteadGainesville$2K
Suresh RamalingamAtlanta$10.5M

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →